Biosimilars Archives

Blog

Priced Out: Generic Therapy Price Competition and Drug Shortages

January 29, 2024

Introduction In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can sometimes be...

Blog

The Implementation Game: The Inflation Reduction Act Medicare Drug Price Negotiation Program Guidance

July 27, 2023

Trinity’s Take Introduction Since the Inflation Reduction Act (IRA) was signed into law in August 2022, biopharma stakeholders have noted the high likelihood of the legislation being challenged in court alongside many questions about how some of the new CMS programs...

money for medicine, within injection needle

Blog

The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future

April 21, 2023

Executive Summary Trinity’s Take Introduction As the second highest grossing drug worldwide, with $21.6 billion in global revenue and $17 billion in U.S. revenue in 2021, AbbVie’s Humira is one of the most commercially successful blockbuster therapies of all time. Humira...

Blog

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

July 20, 2022

Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries [...]